CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 360 enrolled
Drug / intervention
Crenezumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01723826
NCT01723826Phase 2Completed
CompareCT.gov

A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease

Genentech, Inc.·interventional·Posted Nov 8, 2012·Updated Feb 20, 2020

In Brief

A Phase 2 clinical trial evaluating Crenezumab for Alzheimer's Disease. Completed, enrolled 360 participants across 86 sites in 6 countries.

Detailed Summary

This Phase II, open-label extension (OLE), multicenter study will evaluate the long-term safety and tolerability of crenezumab in participants with mild to moderate Alzheimer's disease who have participated in and completed the treatment period of the Phase II Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578). Participants who received placebo in Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578) will receive crenezumab. Anticipated time on study treatment is 144 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesCanada, France, Germany, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 8, 2012
Enrollment StartDec 7, 2012
Primary CompletionFeb 8, 2017
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.7 years ago

Interventions

Crenezumabdrug

Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.